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Introduction: Interethnic variability of drug metabolism has been 
demonstrated across Iberoamerican populations by the CEIBA 
Consortium. Drug-metabolizing enzymes genotype just predicts 
actual drug metabolic activity (phenotype) in the cases of poor 
metabolizers. For example, only 30% of ultrarapid metabolizers 
can be predicted from genotyping (Llerena et al., 2012). Moreover, 
according to EMA recommendations, development of phenotyping 
procedures for drug interactions studies and clinical research recom-
mended (EMA, 2013). Therefore, a novel cocktail approach to meas-
ure metabolic activity (metabolic ratios) of the main CYP enzymes 
in just one experiment is developed and validated to be used in the 
study of Latin-American populations.
Patients (or Materials) and Methods: Subjects were given low 
oral doses of 100-mg caffeine, 25-mg losartan, 20-mg omepra-
zole, and 30-mg dextromethorphan. Blood samples were taken 4 
hours after administering the drugs to assay the following meta-
bolic ratios in plasma: CYP1A2 (caffeine/paraxanthine), CYP2C9 
(losartan /E-3174), CYP2C19 (omeprazole/5-hydroxyomepra-
zole), CYP2D6 (dextromethorphan/ dextrorphan), and CYP3A4 
(dextromethorphan/3-methoxymorphinan). Solid phase extraction 
was utilized for analyte extraction and LC-MS/MS to quantify the 
probe drugs and metabolites.
Results: Recovery values > 80% were obtained for all analytes, and 
no carryover or relative matrix effects were observed. The analytes 
were separated and detected in 9 minutes and the method was fully 
validated, with lower limits of quantification ranging from 0.3 ng 
mL–1 for 5-hydroxyomeprazole to 3.2 ng mL–1 for paraxanthine. 
The correlation coefficient (r2) values obtained were over 0.995 for 
all analytes. According to the EMA guideline on bioanalytical method 
validation, precision and accuracy values below 15% were achieved.
Conclusion: The method was proven to be useful to measure targeted 
analytes for the evaluation of CYPs hydroxylation capacity in just 
a single experiment.
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Introduction: VKORC1, CYP2C9, and CYP4F2 responsible for 
the metabolism of warfarin. Personal and ethnic differences in the 
genetic profile reveals in determining the outcome of a drug therapy. 
Aim: to explore the frequencies of CYP2C9, VCORC1, and CYP4F2 
genotypes in Russians, compare results with ones for other nations
Patients (or Materials) and Methods: A total 91 Caucasian subjects 
were recruited into the study. Forty (48.2%) patients were male and 
age was 66.17 (10.9) years. All patients had indications to receive 
warfarin. Medical records for the patients group were reviewed for 
the relevant clinical data. 5 ml of blood was taken from each subject, 
and DNA was isolated and used for identification of the CYP2C9 
allele *1, *2, *3; G-1639A VCORC1; CYP4F2 V433M rs2108622 
C > T using real-time polymerase chain reaction-restriction fragment 
length polymorphism assay. Results were compared with other ethnic 
groups and statistically analyzed with chi-square test.
Results: We described the prevalence of CYP2C9 polymorphisms *1/*1 
(67%), *1/*2 (9,9%), *1/*3 (11%), *2/*2 (2,2%), *2/*3 (8,8%), same 
for VKORC1 GG (49,5%), GA (28,6%), AA (22,%) and CYP4F2 CC 
(57,1%), CT (34,1%), TT (7,7%). No significant deviantions from 
Hardy-Wainberg equilibrium were observed (p < 0.05). Polymorphisms’ 
frequency of CYP2C9 (P < 0.001) and VKORC1 GG, AA (P < 0.05) in 
Russian distinguish from Asian. There are no significant interethnic vari-
ations for CYP4F2 between Russian, Asian and Caucasian (P > 0.05).
Conclusion: Prevalence of carriage of CYP2C9, VKORC1 polymor-
phisms in Russian patients with high thrombotic risk is closed to 
Caucasians and distinguish from Asians but no for CYP4F2.
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Introduction: CYP3A5 is an enzyme known to be involved in metab-
olism of human hormones – progesterone and testosterone, which 
metabolism may play a role in either disease origin or treatment 
efficacy in women with stillbirth. There is a common genetic poly-
morphism leading to its increased activity (6986*> G). Our aim was 
to investigate possible role of this polymorphism in stillbirth.
Patients (or Materials) and Methods: All women admitted to gyne-
cology department of university clinics with verified diagnoses of still 
birth were considered for recruitment to the study. At the same time 
women who attended routine pregnancy registration were screened 
and recruited at the same time as the study group being matched by 
their age and concomitant diseases. All women who gave informed 
consent were recruited. Peripheral venous blood samples were drawn 
into EDTA tubes. Dna was extracted. Polymerase chain reaction in 
real time was performed to detect genetic variants of CYP3A5 *3/*1 
(6986*> G). Chi-square test was used for frequency comparisons 
using statistical software Graphpad Prizm 5.0.
Results: Fifty-three women with stillbirth were recruited to the study. 
Control group consisted of 92 matched women. Frequency of the minor 
Clinical Therapeutics
e66 volume 35 number 8s
allele A in the study group was 8%, in the control group – 4% (р = 0.1; 
chi-square). The following genotypes distribution was observed in the 
study group: АА – 0.02; AG – 0.13; GG – 0.85. In the control group the 
following genotype distribution was observed: АА – 0.01; AG – 0.05; 
GG – 0.94. Distributions corresponded to Hardy-Weinberg equilibrium.
Conclusion: In our prospective study, we observed tendency to genetic 
predisposition to higher activity of CYP3A5 in women with stillbirth 
compared with matched women with normal pregnancy. The results, 
however, did not reach statistical significance, which may demonstrate 
either lack of real association or insufficient number of subjects recruited. 
The observation needs to be proved or disproved in a larger population.
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Introduction: Venlafaxine, as a substrate of p-glycoprotein, is a 
widely used serotonin-noradrenaline reuptake inhibitor (SNRI). The 
aim of the study is to investigate the influence of ABCB1 G2677T/A, 
C3435T polymorphisms on efficacy of venlafaxine.
Patients (or Materials) and Methods: Patients (n = 52) who met 
the Diagnostic and Statistical Manual of Mental Disorders Fourth 
Edition-IV criteria for major depressive disorder (MDD) were 
enrolled the study. All patients had affirmed for once a day adminis-
tration of venlafaxine at 8:00 to 9:00 am during the study. Protocol 
visits were completed at baseline, 1st, 2nd, 4th, and 6th weeks. 
The clinical response to venlafaxine was evaluated by psychiatrists 
with 17-item Hamilton Rating Scale for Depression (HAM-D17). 
Blood samples were taken for genotyping at 4th week of the study. 
Genotyping for the ABCB1 gene 3435C> T and G2677T/A polymor-
phisms was performed by PCR/RFLP assays.
Results: Our results showed that there is no correlation between effi-
cacy and tolerability of venlafaxine and ABCB1 G2677T/A, C3435T 
polymorphisms. But carriers of the TT genotype for 3435C> T poly-
morphism and carriers of the TT/TA genotype for G2677T/A poly-
morphism could be tended to be poor responder (Table).
Conclusion: Although our results showed that there is no correlation 
between efficacy of venlafaxine and ABCB1 G2677T/A, C3435T pol-
ymorphisms, we couldn’t reach the sufficient patient number. There is 
need for studies with sufficient patient number and haplotype analysis 
including also ABCB1 C1236T polymorphism in MDD patients.
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Introduction: The promise of personalized care has not always 
translated into improvements in patient care. There are concerns 
among payers that advice for certain genetic tests has been revoked, 
diagnostic tests can be costly, and there is fragmentation of funding 
of care including tests. In addition, pharmaceutical companies are 
seeking high prices for new targeted drugs through designating them 
as orphan drugs. Consequently, there is a need to integrate current 
knowledge about the value of genetic, biomarkers, prognostic tests 
and targeted drug therapies from a health authority perspective to 
provide future guidance.
Patients (or Materials) and Methods: This will be achieved by (1) 
reviewing the current literature regarding personalized medicine; 
(2) appraising key funding, organizational, and health care issues 
that need to be addressed especially from a health authority per-
spective; and (3) suggesting future avenues for all key stakeholder 
groups to enhance future funding and utilization of new personalized 
approaches to improve future patient care. The latter will be achieved 
through an iterative process.
Results: Multiple findings are consolidated under headings. These 
include (1) general considerations incorporating definitions and the 
need for different approaches to progress personalized medicine; (2) 
knowledge about the influence of pharmacogenomics on response 
and toxicity of drug therapies using current examples including cases 
where recommendations have recently been revoked; (3) knowledge 
of the value of biomarker tests to target treatment approaches; (4) 
challenges and concerns including the potentially high cost of tests 
and targeted therapies and current fragmentation of funding; and 
(5) key issues for health care funding bodies to address to enhance 
funding for new diagnostic/prognostic tests as well as new targeted 
therapies. Guidance is given on potential ways forward for all key 
stakeholder groups including reviewing key medical, ethical, legal, 
Table.  HAMD17 scores according to ABCB1 G2677T/A, C3435T 
genotypes.
3435C> T 2677g> T/a
CC-CT TT gg-gT-ga TT-Ta
n 41 11 41 11
HAMD17, baseline 21.56 ± 0.695 22.45 ± 2.077 21.78 ± 0.737 21.64 ± 1.865
HAMD17,
1st week 14.93 ± 0.851 16.73 ± 2.195 15.34 ± 0.852 15.18 ± 2.252
HAMD17,
2nd week 13.76 ±0.939 15.64 ± 1.820 13.59 ± 0.907 16.27 ± 1.978
HAMD17,
4th week 11.27 ± 0.968 11.54 ± 1.883 11.24 ± 0.931 12.36 ± 2.125
HAMD17,
6th week 9.63 ± 1.11 10.09 ± 2.095 9.54 ± 1.038 10.45 ± 2.577
F = 0.41, P = 0.741 F = 0.672, P = 0.563
